Is LivaNova (LIVN) Fully Valued Following Strong Q3 Results And Raised 2026 Outlook?
LivaNova (LIVN) just delivered third quarter figures that showed higher sales, positive net income, and a return to profitability over the first nine months, while management lifted its 2026 revenue growth outlook.
LivaNova’s latest results and upgraded 2026 revenue outlook have landed after a strong run, with the share price delivering a 48.4% year to date return and a 78.37% total shareholder return over the past year. However, the 5 year total shareholder return is roughly flat, suggesting recent momentum is a newer shift in how investors are pricing its prospects and risks.
Scan beyond LivaNova and see how other medical and healthcare device stocks with strong fundamentals are setting up in our hand picked list of solid balance sheet and fundamentals (25 results)
LivaNova now carries a much richer share price and sharper growth ambitions. Does the current valuation still leave enough potential to justify taking on new risk for additional buyers?
Most Popular Narrative: 1% Undervalued
LivaNova's most followed valuation story pegs fair value at $90.55, almost exactly in line with the last close of $89.99. As a result, the investment debate now turns on how convincingly execution can support that number over time.
The main thing that has to go right is that LivaNova executes on elevated capital investment in capacity, IT and digital platforms so that cardiopulmonary upgrades, neuromodulation launches and connected care tools translate into sustained profitable growth and improved free cash flow conversion by 2028.
See why 5 investors see LivaNova as 1% undervalued.
Result: Fair Value of $90.55 (UNDERVALUED)
Still, the story can break if elevated 2026 CapEx fails to translate into stronger cardiopulmonary returns, or if epilepsy VNS reimbursement support weakens again.
Find out about the key risks to this LivaNova narrative.
Next Steps
It is normal to have mixed feelings about LivaNova after these results and outlook changes. Move quickly from the initial headline impressions to your own verdict by weighing the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond LivaNova?
Do not stop your research with one stock. Use carefully filtered lists to spot opportunities that fit your goals before others move first.
- Target quality at a discount by scanning a curated group of resilient companies in the 38 high quality undervalued stocks.
- Prioritise staying power and sleep better at night by checking out the 31 resilient stocks with low risk scores.
- Hunt for tomorrow's potential leaders before they hit the spotlight by reviewing the 19 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com